Skin Disorders News

The FDA has issued a complete response letter for Eli Lilly and Company’s lebrikizumab biologics license application for moderate to severe atopic dermatitis treatment, according to a manufacturer-issued press release.

Both methotrexate and cyclosporin are efficacious in the treatment of severe pediatric atopic dermatitis, but methotrexate showed higher rates of sustained treatment response, according to a study.

Children and adolescents with atopic dermatitis treated with long-term dupilumab showed positive results and acceptable safety, according to a meta-analysis of multiple studies.

Nine percent of patients with chronic urticaria experienced exacerbations after getting a COVID-19 vaccination, according to a study published in The Journal of Allergy and Clinical Immunology.

Infants with immature gut microbiota faced greater risks for developing atopic dermatitis, asthma, food allergy and allergic rhinitis by age 5 years, according to a study published in Nature Communications.

Greater atopic dermatitis severity correlated with greater disease burden in children and adolescents in Japan, according to a study.

Healio compiled the most-read news in allergy, asthma and immunology posted in August.

Changes in the gut microbiota of infants preceded the development of eczema, according to a study published in mSystems.

Treatment with dupilumab reduced Staphylococcus aureus colonization and infection in patients with atopic dermatitis, correlating with improved outcomes, according to a study published in The Journal of Allergy and Clinical Immunology.

Atopic dermatitis was associated with increased odds for schizophrenia and schizoaffective disorder, according to a study published in Archives of Dermatological Research.